Open AccessProgramed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients
Author(s) -
Amanda L. Gill,
Samantha A. Green,
Shahed Abdullah,
Cécile Le Saout,
Stefania Pittaluga,
Hui Chen,
Refika Turnier,
Jeffrey D. Lifson,
Steven Godin,
Jing Qin,
Michael C. Sneller,
Jean-Marie Cuillerot,
Helen Sabzevari,
H. Clifford Lane,
Marta Catálfamo
Publication year - 2016
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000001217
Subject(s) - simian immunodeficiency virus , immunology , blockade , medicine , lymph node , immunopathology , immune system , antibody , virus , viral load , chronic infection , immune checkpoint , virology , receptor , immunotherapy
The programed death-1 (PD1)/programed death-ligand 1 (PD-L1) pathway plays a critical role in balancing immunity and host immunopathology. During chronic HIV/SIV infection, there is persistent immune activation accompanied by accumulation of virus-specific cells with terminally differentiated phenotypes and expression of regulatory receptors such as PD1. These observations led us to hypothesize that the PD1/PD-L1 pathway contributes to the functional dysregulation and ineffective viral control, and its blockade may be a potential immunotherapeutic target.